Cytomx Therapeutics (CTMX) – Market Snapshot and Contextual Insights
Recent Performance
CTMX closed up 1.67 % during the 24‑hour period ending 11:44 PM CET on Friday, 23 November 2026.
The current trading price on major exchanges is USD 2.32 per share.
Shares outstanding: 217.9 million.
Market capitalization: USD 523 million.
Volume in the last 24 hours: USD 6 million of shares traded.
Trend Analysis
Since the end of last month, the stock has declined 12.23 %, underscoring a recent bearish trajectory.
The 200‑day simple moving average sits at USD 3.93, indicating that the current price is below the long‑term trend line.
Over the past 52 weeks, CTMX’s high was USD 8.21 (16 March 2026) and its low was USD 2.20 (14 October 2026).
The present price of USD 2.32 lies roughly 71 % above the 52‑week low, suggesting a potential upside if the stock rebounces toward its peak.
Peer Comparison – 24‑Hour Performance
| Company | 24‑Hour Move | Current Price (USD) | Market Cap (USD mn) | Key Highlights |
|---|---|---|---|---|
| Orthopediatrics (KIDS) | +3.65 % | 24.5 | 622.5 | Strong earnings beat; expanding pediatric oncology pipeline. |
| Zevra Therapeutics (ZVRA) | –0.29 % | 9.81 | 615.2 | P/E of 10.82; ongoing phase‑III trials for neuroblastoma. |
| Gyre Therapeutics (GYRE) | –0.68 % | 5.85 | 625.6 | Recent CEO/COO appointment; new management’s compensation packages disclosed. |
| Olema (OLMA) | –2.76 % | 6.41 | 616.9 | Volatility driven by regulatory updates. |
| Climb Bio (CLYM) | +0.65 % | 10.19 | 624.3 | Incremental growth in immunotherapy portfolio. |
Strategic Outlook for Cytomx Therapeutics
Cytomx Therapeutics remains a focused oncology player, developing probody therapeutics that aim to deliver potent anti‑cancer agents while mitigating off‑target toxicity. The company’s pipeline, coupled with a robust intellectual property portfolio, positions it well within a market that increasingly values precision medicine.
- Pipeline Momentum
- Several probody candidates have advanced to clinical stages, with upcoming data expected from ongoing Phase II studies.
- A successful clinical outcome could catalyze a price rebound, potentially elevating the stock above its 200‑day average.
- Capital Efficiency
- With a market cap of USD 523 million and a modest trading volume, CTMX maintains a low dilution profile.
- The company’s IPO in 2015 and subsequent share issuance history suggest disciplined capital allocation.
- Competitive Landscape
- Peer companies such as Orthopediatrics and Gyre Therapeutics are experiencing modest gains, reflecting investor optimism in niche oncology sectors.
- CTMX’s focus on probody technology differentiates it from competitors relying on traditional antibody formats.
- Risk Considerations
- The recent 12 % decline indicates sensitivity to broader market swings or specific company news that may not have materialized yet.
- The stock’s proximity to the 52‑week low warrants caution; investors should monitor upcoming clinical data releases and regulatory filings.
Conclusion
Cytomx Therapeutics (CTMX) currently trades at USD 2.32, well below its 200‑day moving average but above its recent 52‑week low. The company’s specialized probody platform offers a compelling value proposition amid a competitive oncology landscape. While the stock has faced a modest downturn since the previous month, the potential for pipeline milestones to drive a recovery remains significant. Investors observing the oncology biopharma sector should keep a close eye on Cytomx’s clinical progress and market positioning, as these factors will likely dictate the stock’s trajectory in the coming quarters.
